First in Human, Dose Escalation, Dose Expansion Study of AUR105
Status:
Not yet recruiting
Trial end date:
2026-05-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, First in Human, Phase 1 study of AUR 105 in adult
patients with advanced malignancies.
The study will have two parts: a Dose Escalation Part and Dose Expansion Part.